日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial

基于 EMPA-KIDNEY 临床试验,评估恩格列净 (JARDIANCE®) 在法国治疗慢性肾病患者的成本效益

Groyer, Harinala; Supiot, Romain; Tardu, Jean; Virely, Nicolas; Sivignon, Marine; San, Denis; Lévy, Pierre; Ustyugova, Anastasia; Massy, Ziad A

Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial

基于 EMPEROR-Preserved 临床试验,评估恩格列净 (JARDIANCE®) 在法国治疗射血分数保留型心力衰竭患者的公共卫生影响和成本效益

Fauchier, Laurent; Lamblin, Nicolas; Tardu, Jean; Bellier, Lucile; Groyer, Harinala; Ittah, Deborah; Chollet, Julien; Linden, Stephan; Levy, Pierre

Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40

恩格列净治疗射血分数>40%的心力衰竭患者的多国成本效益分析

Kolovos, Spyros; Bellanca, Leana; Groyer, Harinala; Rosano, Giuseppe M C; Solé, Alexandra; Gaultney, Jennifer; Linden, Stephan

Hospital Resource Utilization and Costs in Patients with Heart Failure in France

法国心力衰竭患者的医院资源利用情况和成本

Chemouni, Frank; Nishikawa, Tiffany Chihiro; Groyer, Harinala; Diaby, Oumou; Chollet, Julien; Ittah, Deborah

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England

在英国,无论射血分数如何,恩格列净治疗心力衰竭患者的成本效益分析

Kolovos, Spyros; Bellanca, Leana; Groyer, Harinala; Rosano, Giuseppe; Gaultney, Jennifer; Linden, Stephan